Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

July 24, 2025

Study Completion Date

July 24, 2026

Conditions
AL Amyloidosis
Interventions
DRUG

Bortezomib

Given SC

DRUG

Cyclophosphamide

Given IV or PO

DRUG

Dexamethasone

Given IV or PO

BIOLOGICAL

Isatuximab

Given IV

Trial Locations (6)

10032

Columbia University, New York

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

39322

Emory University Hospital Midtown, Atlanta

48201

Karmanos Cancer Institute, Detroit

75390

UT Southwestern, Dallas

92868

University of California, Orange

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER